New immunotherapy combo aims to tackle tough lung cancer
NCT ID NCT07009457
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental drug called SHR-1316, given as a shot under the skin, together with standard chemotherapy (carboplatin and etoposide) in people with extensive-stage small cell lung cancer who have not had prior treatment. The study looks at how the drug moves through the body, its safety, and whether it helps shrink tumors. About 24 participants will take part to gather initial information on dosing and effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1316 (an experimental immunotherapy) combined with carboplatin and etoposide (chemotherapy)
- What this could lead to
- If successful, this could lead to a new first-line treatment option for extensive-stage small cell lung cancer, potentially improving tumor control and survival.
- What could go wrong
- This is an early Phase 1 trial with only 24 participants, so safety and effectiveness are not yet established. The combination may cause significant side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WIDESPREAD SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330200, China